Zydus Lifesciences Ltd Stock Price Today (NSE: ZYDUSLIFE)
Fundamental Score
Zydus Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zydus Lifesciences Ltd share price today is ₹864.25, up +0.12% on NSE/BSE as of 14 April 2026. Zydus Lifesciences Ltd (ZYDUSLIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹94.25K (Cr). The 52-week high for ZYDUSLIFE share price is ₹1059.05 and the 52-week low is ₹813.00. At a P/E ratio of 18.74x, ZYDUSLIFE is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.21% and a debt-to-equity ratio of 0.38.
Zydus Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-09
Zydus is betting on a US specialty pharma pivot, but execution is key amid generics headwinds.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Zydus Lifesciences' stock is up 1.73% today, quoting ₹907 on the NSE, rising for the fifth straight session. However, it has slipped around 1.74% in the last month. On April 8, 2026, the company announced it had received FDA approval for its generic dapagliflozin tablets (5mg and 10mg), targeting a market with annual sales exceeding $10 billion. 🧠 CORE STORY (THE REAL GAME): Zydus is transitioning from a generics player to a specialty pharma and biologics company, focusing on the US market and high-value segments like biosimilars and complex generics. The market is watching to see if Zydus can successfully execute this transition and achieve sustainable, high-margin growth. 🔥 WHAT IS DRIVING THE STOCK: * **US FDA Approvals:** Dapagliflozin approval drives potential revenue in a $10 billion market. * **Export Growth:** Indian pharma exports are up 5.6% in FY26, providing a macro tailwind. * **Acquisitions:** Strategic acquisitions like Agenus are expanding manufacturing capabilities in biologics. ⚖️ BULL vs BEAR: Bull: New product launches and expansion of the US specialty drug business are key growth catalysts. Analyst consensus target is ₹1,050-1,200. Bear: Generics pricing pressure, delayed FDA approval for biosimilar saroglitazar (pushed to H1 FY27), and potential ₹400-500 crore annualised revenue impact from Asacol HD generics competition. 💣 WHAT MARKET IS PRICING: The market is pricing in continued success in obtaining US FDA approvals and a smooth transition to higher-margin specialty products. A failure to launch key products or increased pricing pressure in the US generics market could lead to a derating. 🎯 BOTTOM LINE: Zydus is a complex story undergoing a strategic shift; execution risk is high, but the potential reward is significant if they can successfully navigate the US market.
- FDA approval for Dapagliflozin targets a $10B market
- Indian pharma exports are growing, providing a tailwind
- Strategic acquisitions are expanding manufacturing capabilities
- Successful launch of Dapagliflozin in the US
- Positive outcome from US FDA filing for Saroglitazar Magnesium
- Further strategic acquisitions to expand product portfolio
- Generics pricing pressure in the US
- Delayed FDA approval for biosimilar Saroglitazar
- Potential revenue impact from Asacol HD generics competition
FII increased their stake by 0.21% while DII decreased by 0.23% [cite: brief].
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand.
Yes, Free Cash Flow 5Y: ₹12623.1 Cr [cite: brief].
Zydus aims to strengthen its position in the US market through new product launches and strategic acquisitions. Success hinges on navigating regulatory hurdles and competitive pressures.
Primary Thesis Risk
Failure to successfully transition to specialty pharma and biologics will crush the valuation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Zydus Lifesciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Zydus Lifesciences Share Price: A Financial Stability Analysis
One key industry insight in the pharmaceutical sector is the increasing emphasis on research and development (R&D) for novel drug discoveries and generic formulations, directly impacting long-term growth. This analysis explores the financial stability of Zydus Lifesciences, focusing on factors influencing the Zydus Lifesciences share price. The current price stands at ₹888.150024, with a Price-to-Earnings (PE) ratio of 18.74 and a Return on Capital Employed (ROCE) of 24.31%. This report is a segment of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra.
A crucial aspect of evaluating Zydus Lifesciences' financial health is its profitability. The PE ratio of 18.74 suggests a market expectation of future earnings growth, though a deeper dive into earnings quality is essential. Comparing Zydus Lifesciences Ltd with peers like
Mankind Pharma Ltd, the management's strategic decisions regarding R&D investment and operational efficiency are particularly relevant. While Mankind Pharma Ltd may exhibit strengths in different areas, a comparative assessment of management quality necessitates analyzing capital allocation decisions and responses to regulatory changes.The ROCE of 24.31% is a significant indicator of Zydus Lifesciences' capital efficiency. This robust ROCE contributes directly to strengthening the company's economic moat. A higher ROCE means the company generates more profit from its invested capital, allowing it to reinvest in growth opportunities, such as new product development or market expansion, more effectively than competitors with lower ROCEs. This strengthens its competitive advantage and sustains profitability.
Considering the provided data, further in-depth analysis is warranted. This includes assessing the company's debt levels, cash flow generation, and the sustainability of its ROCE. Competitor analysis within the sector, including Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, would provide a more nuanced understanding of Zydus Lifesciences' relative financial position and potential risks. The analysis presented observes current data points; a conclusion on investment is not provided.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zydus Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZYDUSLIFE across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (21.21%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.31%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (25.73%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 18.74 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (40.92%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.92%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (26.36% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.92% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (23.80x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹12623.10 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Zydus Lifesciences Ltd Financial Statements
Comprehensive financial data for Zydus Lifesciences Ltd including income statement, balance sheet and cash flow
About ZYDUSLIFE (Zydus Lifesciences Ltd)
Zydus Lifesciences Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing global health. The company meticulously researches..., develops, manufactures, and distributes a wide spectrum of pharmaceutical products catering to diverse therapeutic areas. With a strong presence in India, the United States, and numerous international markets, Zydus Lifesciences is dedicated to addressing unmet medical needs and improving patient outcomes worldwide. Their infrastructure supports end-to-end pharmaceutical solutions, from drug discovery to commercialization, ensuring quality and accessibility across its product range. They are constantly striving to improve health outcomes and the quality of life across the globe. The organization operates through distinct divisions focused on Pharmaceuticals, which are its central activity. They make active pharmaceutical ingredients, finished formulas for doses, generics, biosimilars, novel products, and specialty products. It also has a division dedicated to Consumer Products. This dual focus allows Zydus Lifesciences to leverage its scientific expertise to create both prescription medications and over-the-counter healthcare solutions. The company's dedication to research and development is evident in its consistent introduction of innovative products and therapies. Zydus Lifesciences distinguishes itself through its dedication to quality, safety, and affordability, making it a trusted partner in healthcare. Zydus Lifesciences extends its reach beyond prescription medications through a well-established portfolio of well-known consumer brands. These include brands in personal care, food and nutrition, and everyday health. These product lines, which include personal care products, nutritional supplements, and wellness goods, reflect the company's comprehensive approach to health and well-being. They are dedicated to providing accessible and high-quality options to consumers. Through this multi-pronged strategy, Zydus Lifesciences continues to expand its footprint in the healthcare industry, further solidifying its position as a leading and responsible global healthcare provider.
Company Details
Key Leadership
Corporate Events
Latest News
ZYDUSLIFE Share Price: Frequently Asked Questions
What is the current share price of Zydus Lifesciences Ltd (ZYDUSLIFE)?
As of 14 Apr 2026, 11:00 am IST, Zydus Lifesciences Ltd share price is ₹864.25. The ZYDUSLIFE stock has a market capitalisation of ₹94.25K (Cr) on NSE/BSE.
Is ZYDUSLIFE share price Overvalued or Undervalued?
ZYDUSLIFE share price is currently trading at a P/E ratio of 18.74x, compared to the industry average of 31.77x. Based on this relative valuation, the Zydus Lifesciences Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ZYDUSLIFE share price?
The 52-week high of ZYDUSLIFE share price is ₹1059.05 and the 52-week low is ₹813.00. These values are updated daily from NSE/BSE price data.
What factors affect the Zydus Lifesciences Ltd share price?
Key factors influencing ZYDUSLIFE share price include quarterly earnings growth (Sales Growth: 16.92%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zydus Lifesciences Ltd a good stock for long-term investment?
Zydus Lifesciences Ltd shows a 5-year Profit Growth of 25.92% and an ROE of 21.21%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.38 before investing in ZYDUSLIFE shares.
How does Zydus Lifesciences Ltd compare with its industry peers?
Zydus Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare ZYDUSLIFE share price P/E of 18.74x and ROE of 21.21% against the industry averages to determine competitive standing.
What is the P/E ratio of ZYDUSLIFE and what does it mean?
ZYDUSLIFE share price has a P/E ratio of 18.74x compared to the industry average of 31.77x. Investors pay ₹19 for every ₹1 of annual earnings.
How is ZYDUSLIFE performing according to Bull Run's analysis?
ZYDUSLIFE has a Bull Run fundamental score of 68.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ZYDUSLIFE belong to?
ZYDUSLIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zydus Lifesciences Ltd share price.
What is Return on Equity (ROE) and why is it important for ZYDUSLIFE?
ZYDUSLIFE has an ROE of 21.21%, which indicates excellent management efficiency. ROE measures how efficiently Zydus Lifesciences Ltd generates profits from shareholders capital.
How is ZYDUSLIFE debt-to-equity ratio and what does it indicate?
ZYDUSLIFE has a debt-to-equity ratio of 0.38, which indicates moderate leverage that should be monitored.
What is ZYDUSLIFE dividend yield and is it a good dividend stock?
ZYDUSLIFE offers a dividend yield of 1.17%, meaning you receive ₹1.17 annual dividend for every ₹100 invested in Zydus Lifesciences Ltd shares.
How has ZYDUSLIFE share price grown over the past 5 years?
ZYDUSLIFE has achieved 5-year growth rates of: Sales Growth 10.27%, Profit Growth 25.92%, and EPS Growth 26.36%.
What is the promoter holding in ZYDUSLIFE and why does it matter?
Promoters hold 74.99% of ZYDUSLIFE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Zydus Lifesciences Ltd.
What is ZYDUSLIFE market capitalisation category?
ZYDUSLIFE has a market capitalisation of ₹94254 crores, placing it in the Large-cap category.
How volatile is ZYDUSLIFE stock?
ZYDUSLIFE has a beta of N/A. A beta > 1 suggests the Zydus Lifesciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ZYDUSLIFE operating profit margin trend?
ZYDUSLIFE has a 5-year average Operating Profit Margin (OPM) of 25.73%, indicating the company's operational efficiency.
How is ZYDUSLIFE quarterly performance?
Recent quarterly performance shows Zydus Lifesciences Ltd YoY Sales Growth of 16.92% and YoY Profit Growth of 40.92%.
What is the institutional holding pattern in ZYDUSLIFE?
ZYDUSLIFE has FII holding of 7.34% and DII holding of 10.86%. Significant institutional holding often suggests professional confidence in the Zydus Lifesciences Ltd stock.